PMID- 20926543
OWN - NLM
STAT- MEDLINE
DCOM- 20101115
LR  - 20191210
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 95
IP  - 10
DP  - 2010 Oct
TI  - Elevated insulin-like growth factor-I values in children with Prader-Willi 
      syndrome compared with growth hormone (GH) deficiency children over two years of 
      GH treatment.
PG  - 4600-8
LID - 10.1210/jc.2009-1831 [doi]
AB  - BACKGROUND: Children with Prader-Willi syndrome (PWS) are routinely treated with 
      GH and have a response comparable with that observed in children with GH 
      deficiency (GHD). OBJECTIVE: The objective of the study was to compare changes in 
      serum IGF-I, IGF binding protein 3 (IGFBP-3), IGF-I to IGFBP-3 molar ratio, and 
      growth velocity during the first 2 yr of GH therapy in PWS and GHD children. 
      SUBJECTS AND METHODS: Thirty-three children with PWS (14 boys, 4.9 +/- 3.8 yr) and 
      591 with GHD (351 boys, 9.6 +/- 3.6 yr), all naive to GH treatment, were included 
      in this study. Serum IGF-I and IGFBP-3 were measured at 0, 6, 12, and 24 months 
      of GH therapy. The mean initial dose of GH was 0.9 and 1 mg/m(2) . d in the PWS 
      and GHD groups, respectively. RESULTS: Mean +/- SD IGF-I sdscore (SDS) and IGFBP-3 
      SDS were significantly higher in PWS compared with GHD. The IGF-I to IGFBP-3 
      molar ratio was significantly lower at baseline and subsequently not different. 
      Despite significantly lower GH doses in PWS children at 6, 12, and 24 months (P = 
      0.021, P = 0.021, P = 0.001), IGF-I reached 2.8 +/- 1.2 SDS at 24 months (72% of 
      values > 2 SDS), and remained at 0.7 +/- 1.6 SDS in GHD children (17% of values > 2 
      SDS). IGFBP-3 did not exceed 2 SDS in either group. There was no significant 
      change in the IGF-I to IGFBP-3 molar ratio. CONCLUSIONS: IGF-I SDS increases to a 
      greater extent in PWS than GHD. Bioavailable IGF-I is apparently not different, 
      suggesting that any possible safety issues related to elevated IGF-I are similar 
      in both groups.
FAU - Feigerlova, Eva
AU  - Feigerlova E
AD  - Department of Endocrinology, Bone Diseases, Genetics, and Gynaecology, Centre de 
      Reference du Syndrome de Prader-Willi, Children's Hospital, Toulouse, France.
FAU - Diene, Gwenaelle
AU  - Diene G
FAU - Oliver, Isabelle
AU  - Oliver I
FAU - Gennero, Isabelle
AU  - Gennero I
FAU - Salles, Jean-Pierre
AU  - Salles JP
FAU - Arnaud, Catherine
AU  - Arnaud C
FAU - Tauber, Maithe
AU  - Tauber M
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 12629-01-5 (Human Growth Hormone)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Body Mass Index
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Dwarfism, Pituitary/blood/*drug therapy/metabolism
MH  - Female
MH  - Growth Charts
MH  - Growth Disorders/*blood/complications/*drug therapy/metabolism
MH  - Hormone Replacement Therapy
MH  - Human Growth Hormone/deficiency/*therapeutic use
MH  - Humans
MH  - Infant
MH  - Insulin-Like Growth Factor Binding Protein 3/blood
MH  - Insulin-Like Growth Factor I/*metabolism
MH  - Male
MH  - Prader-Willi Syndrome/*blood/complications/*drug therapy/metabolism
MH  - Up-Regulation
EDAT- 2010/10/12 06:00
MHDA- 2010/11/16 06:00
CRDT- 2010/10/08 06:00
PHST- 2010/10/08 06:00 [entrez]
PHST- 2010/10/12 06:00 [pubmed]
PHST- 2010/11/16 06:00 [medline]
AID - 95/10/4600 [pii]
AID - 10.1210/jc.2009-1831 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2010 Oct;95(10):4600-8. doi: 10.1210/jc.2009-1831.